Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges Post author:Sam Post published:August 29, 2017 Post category:BioPharma August 30, 2017By Alex Keown, BioSpace… Source: BioSpace You Might Also Like DBV Technologies Reports Positive Data from Milk Allergy Trial February 26, 2018 Cambrex Corporation To Announce First Quarter 2017 Financial Results On May 4, 2017 May 1, 2017 Bay Area's AirXpanders Bags $34 Million In Private Placement January 29, 2017
